Precision radiopharmaceuticals for cancer treatment

Precision radio­pharma­ceuticals

PRECIRIX® is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies (sdAb) labelled with radiometals.

The company's lead program targets Fibroblast Activation Protein (FAP) and is transitioning into the clinic. It has the potential to be the first in class alpha-emitting targeted radiotherapy against the pan tumor target FAP. Research on multiple isotopes, linker technology and combination therapies is ongoing to further expand the platform.

Company Presentation

Join our team

At Precirix we care about people. We strive to improve the lives of cancer patients by developing novel radiopharmaceuticals that address unmet medical needs. We bring together a unique and varied set of talents to accomplish this goal. If you are interested in joining our multidisciplinary team, you can find the list of vacancies here: Current Vacancies

Get in touch